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Background: Dicer and Drosha are important enzymes for processing microRNAs. Recent studies have exhibited
possible links between expression of different miRNAs, levels of miRNA processing enzymes, and cancer prognosis.
We have investigated the prognostic impact of Dicer and Drosha and their correlation with miR-126 expression in a
large cohort of non-small cell lung cancer (NSCLC) patients. We aimed to find patient groups within the cohort that
might have an advantage of receiving adjunctive therapies.
Methods: Dicer expression in the cytoplasm and Drosha expression in the nucleus were evaluated by manual
immunohistochemistry of tissue microarrays (TMAs), including tumor tissue samples from 335 patients with
resected stages I to IIIA NSCLC. In addition, in situ hybridizations of TMAs for visualization of miR-126 were
performed. Kaplan–Meier analysis was performed, and the log-rank test via SPSS v.22 was used for estimating
significance levels.
Results: In patients with normal performance status (ECOG = 0, n = 197), high Dicer expression entailed a significantly
better prognosis than low Dicer expression (P = 0.024). Dicer had no significant prognostic value in patients with
reduced performance status (ECOG = 1–2, n = 138). High Drosha expression was significantly correlated with high levels
of the microRNA 126 (miR-126) (P = 0.004). Drosha/miR-126 co-expression had a significant negative impact on the
disease-specific survival (DSS) rate (P < 0.001). Multivariate analyses revealed that the interaction Dicer*Histology
(P = 0.049) and Drosha/miR-126 co-expression (P = 0.033) were independent prognostic factors.
Conclusions: In NSCLC patients with normal performance status, Dicer is a positive prognostic factor. The importance
of Drosha as a prognostic factor in our material seems to be related to miR-126 and possibly other microRNAs.
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Lung cancer is a heterogeneous disease and a leading
cause of cancer-related death in most developed countries.
Although there have been advances in treatment over the
past few years, the 5-year disease-specific survival (DSS)
rate is still < 15%. Therefore, it is important to investigate
possible prognostic factors among the survivors in order* Correspondence: kentosj@gmail.com
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unless otherwise stated.to gain a better understanding of NSCLC malignancy and
to develop treatment options for different NSCLC patient
subgroups [1].
Recently, an increasing number of reports have impli-
cated a role for miRNAs in lung cancer progression [2,3].
MicroRNAs are potential targets for treating NSCLC car-
cinomas [4], and research has focused on the diagnostic
and prognostic potential of different microRNAs (miR-
NAs or miRs) in NSCLC. It is believed that miRNA ex-
pression is important in NSCLC development [5,6].
Expression profiling of miRNAs in normal and diseased
lung tissues have revealed unique expression patterns, andLtd. This is an Open Access article distributed under the terms of the Creative
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suppressor genes or oncogenes [7-13].
Several studies have identified miR-126 as a novel
prognostic marker for predicting the overall survival rate
of patients with some types of cancer [14,15]. MiR-126
has been found to be expressed predominantly by endo-
thelial cells, thereby influencing angiogenesis [16,17] by
downregulation of VEGF-A expression through the
interaction with the 3’-untranslated region [18]. An
independent and tissue-specific prognostic impact of
miR-126 has been demonstrated in NSCLC, where co-
expression of miR-126 with vascular endothelial growth
factor-A (VEGF-A) predicts poor survival [19]. Other re-
search has implied that mir-126 inhibits tumor cell
growth, and its expression level correlates with poor sur-
vival of NSCLC patients [7]. The expression and roles of
miR-126 might be different in various malignancies
where miR-126 is downregulated, thereby acting as po-
tential tumor suppressor [19-22].
Understanding the biogenesis of miRNAs has caught
the interest of many researchers, and several papers have
been published that focus on the enzymes necessary for
synthesizing miRNAs [23-25]. MicroRNAs are generated
in a two-step processing pathway mediated by two major
enzymes, Dicer and Drosha, both of which belong to the
class of RNase III endonucleases. The intranuclear
miRNA processing enzyme Drosha and the extranuclear
microRNA-processing enzyme Dicer play pivotal roles in
miRNA maturation. Drosha is part of a multiprotein
complex that mediates the nuclear processing of the pri-
mary miRNAs into stem-loop precursors (pre-miRNA).
In the cytoplasm, the pre-miRNA is cleaved by Dicer
into mature nucleotide miRNA. In the biogenesis of the
majority of miRNAs, both Dicer and Drosha are neces-
sary factors, together with several other proteins in-
volved in the miRNA processing machinery [23,26].
Dicer and Drosha seem to have a prognostic impact, and
both have been found to be differentially expressed in
various cancer tissue types when compared to normal
tissue [27-32].
The Eastern Cooperative Oncology Group (ECOG)
performance status [33] provides scales and criteria for
assessing how a patient’s disease is progressing and helps
to determine appropriate treatment options and progno-
sis. Many studies include patients with an ECOG per-
formance status grade of 0 and 1 only. Patients in these
groups are either, fully active and able to carry on all
pre-disease performance without restrictions, or are re-
stricted in physically strenuous activity and able to carry
out work of a light or sedentary nature. In this study we
have also included NSCLC patients with an ECOG grade
of 0–2 that are capable of all self-care but unable to
carry out any work activities and have more than 50% of
waking hours. Cancer patients with an ECOG grade of3–4 have reduced survival regardless of other clinical
and pathological variables.
Although several studies have been performed on differ-
ent cancer types in order to elucidate and decipher the
roles of Dicer and Drosha in carcinogenesis and their po-
tential impact on prognosis, the contribution of Dicer and
Drosha on miR-126 expression in NSCLC has not been
addressed. Therefore, this study investigates the possible
prognostic value of the expression of the miRNA regula-




The study was approved by The National Data Inspection
Board, The Regional Committee for Research Ethics (REK
Nord). The Regional Committee for Research Ethics spe-
cifically waived the need for consent, since this is a retro-
spective study with more than half of patients deceased.
Patients and clinical samples
The study examined primary tumor tissues from anon-
ymized patients diagnosed with NSCLC pathologic stage
I to IIIA within the period from 1990 to 2004 at the
University Hospital of North Norway (UNN) and Nord-
land Central Hospital (NLCH). During this period adju-
vant chemotherapy had not yet been introduced in
Norway. Thus, 371 patients were considered as potential
candidates for this study, of which 36 patients were ex-
cluded due to (i) chemotherapy or radiotherapy prior to
surgery (n = 10), (ii) other malignancy within five years
prior to NSCLC diagnosis (n = 13), and (iii) inadequate
paraffin-embedded fixed tissues (n = 13). The analysis
was, therefore, left with 335 patients with complete
medical records and adequate paraffin-embedded tis-
sues. All prognostic clinicopathologic variables as pre-
dictors for DSS in 335 NSCLC patients are summarized
in Additional file 1: Table S1 and were reported in a pre-
vious study [19].
The NSCLC patients included in this study have an
ECOG rating of 0, 1, or 2, where normal performance
status is equal to 0 and reduced performance status is 1
or 2. NSCLC patients are rated from 0–5, but only pa-
tients with ratings from 0–2 are eligible for surgery. The
rating system has been explained in detail in previous
publications [33] and http://www.ecog.org/general/perf_-
stat.html.
All tumor tissues were selected at primary surgery of
previous non-treated lung cancer patients and the follow-
up started directly after surgery. The last follow-up data
included was from November 30, 2008. The median
follow-up for survivors was 86 (range 48–216) months.
The tumors were staged according to the new 7th edition
of TNM classification in Lung Cancer and histologically
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ganization’s guidelines [34,35].
Immunohistochemistry (IHC)
All lung cancer cases were histologically reviewed by two
experienced pathologists (Samer Al-Saad and Khalid
Al-Shibli), and the most representative areas of viable
tumor cells (neoplastic epithelial cells) were carefully se-
lected. Within these areas, four cores from each patient
were randomly sampled and assembled in TMA (tissue
microarray) blocks. The detailed methodology has been re-
ported previously [36]. As controls served samples of nor-
mal lung tissue localized distant from the primary tumor,
and normal lung tissue samples from 20 patients without
any cancer diagnosis (see Additional file 2: Figure S1). Mul-
tiple 4 μm sections were cut with a Microm microtome
(HM355S) and analyzed via immunohistochemistry with
regard to the miRNA regulators Dicer and Drosha.
Specific antibodies for Dicer (13D6-ChIP grade,
ab14601) and Drosha (ab85027) (both Abcam, Cambridge,
UK) have been validated in-house by the manufacturer for
IHC analysis on paraffin-embedded material prior to use.
Sections were deparaffinized with xylene and rehydrated
through graded ethanol series (Drosha) or by using
Ventana reagents for automatic staining of Dicer (Ventana
BenchMark XT, Ventana Medical Systems Inc.). Manual
antigen retrieval (for Drosha) was performed by placing
the specimens in a 10 mM Tris–HCl/1 mM EDTA buffer,
with pH 9.0, and subsequent microwave heating for 20 -
minutes at 450 W. Automatic antigen retrieval (for Dicer)
(Ventana Benchmark XT) was performed by heating the
sections for 30 minutes in a Tris-based buffer (CC1 mild).
Staining was performed with a detection reagent con-
taining a secondary antibody plus an avidin-biotin en-
zyme complex (manual procedure), or a polymer of
secondary antibodies conjugated with an enzyme (Ven-
tana). Primary antibodies were diluted at 1:20 (Dicer)
and 1:100 (Drosha) or incubated overnight at room
temperature (Drosha) and for 32 minutes at 37°C
(Dicer). Diaminobenzidine (DAB) was used to visualize
the antigens. The detection system in the Ventana XT
was the ultraView DAB. Finally, counterstaining was
performed with hematoxylin and by mounting the
slides. In negative control slides, the primary antibody
was replaced with the primary antibody diluent, and for
positive staining controls, we used breast carcinoma
samples (data not shown).
In Situ Hybridization (ISH)
The in situ hybridization method was adapted from [37]
and performed with minor adjustments due to different
batches of labelled probes. In situ hybridizations of
TMA sections for visualization of miR-126 were essen-
tially performed in accordance with recent research [19].Scoring of IHC
The IHC-stained TMA slides were scanned with the
ARIOL imaging system (Genetix, San Jose, CA) as fol-
lows: The slides were loaded in the automated loader
(Applied Imaging SL 50) and TMA slides were scanned
at low (1.25 x) and high resolutions (20 x) by using the
Olympus BX 61 microscope with an automated plat-
form. Representative and viable tissue sections were
scored manually and semi-quantitatively for cytoplasmic
staining (Dicer) and for staining the tumor cell nuclei
(Drosha) via a computer screen. The average staining in-
tensity of the majority of cells was scored as 0 = negative,
1 = weak, 2 = intermediate, and 3 = strong (see Figures 1
and 2), as described previously [36]. In case of disagree-
ment (score variance > 1), the slides were re-examined
and an agreement was reached by the observers. In most
cores there was a mixture of stromal cells and tumor
cells. By morphological criteria only tumor cells were
scored for staining intensity.
All samples were anonymized and independently
scored by an experienced pathologist and a technician
(S.W.S. and K.L.). When scoring the samples, the ob-
servers were blind to the scores of the other observer
and to the outcome. The mean score for each case was
calculated from all four cores by both examiners. High
expression of both Dicer and Drosha in neoplastic
tumor cells was defined as a mean score ≥ 2. This cut-off
value was selected to find the two groups with the lar-
gest possible difference in survival. It is hereby noted
that the results might be depended on the choice of the
cut-off value. However, for miR-126 we used the same
cut-off value and the same scoring system as previously
described in detail [19,38].
Inter-observer variability
An inter-observer scoring agreement was tested for both
Dicer and Drosha, and the agreement was robust (r =
0.92, P < 0.001).
Statistical methods
In brief, statistical analyses were conducted with the statis-
tical package SPSS (Chicago, IL), version 22. The Chi-square
test and Fisher’s exact test were used to examine the associ-
ation between Dicer and Drosha expressions and various
clinicopathological parameters. The IHC scores from each
observer were compared for inter-observer reliability by use
of a two-way random effect model with absolute agreement
definition. The intraclass correlation coefficient (reliability
coefficient) was obtained from these results. The Kaplan–
Meier method was used to plot DSS according to expression
levels, and statistical significance between survival curves
was assessed by the log-rank test. DSS was determined from
the date of surgery to the time of death from lung cancer.
The multivariate analysis was conducted with the Cox
Figure 1 Disease-specific survival and overall survival curves for histology (A and B) and ECOG (C and D) including all patients. SCC
indicates squamous cell carcinoma.
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cant value from the univariate analysis were entered into the
Cox regression analysis. Differences in expression of Dicer,
Drosha, and miR-126 as continuous variables by histology
are analyzed using ANOVA. The significance level employed
was P < 0.05.
Results
Overall NSCLC patient group characteristics
The NSCLC patient cohort comprised 253 males (75%)
and 82 females (25%), (Additional file 1: Table S1). The
follow-up time was up to 250 months (20 years). During
follow-up, 236 (70%) patients died, 137 (40%) from lung
cancer and 99 (30%) from other reasons (data not shown).
The 5- year DSS was 56% for males and 63% for females
(Additional file 1: Table S1). On a continuous scale (0–3),
the mean expression of Dicer, Drosha, and miR-126 in all
patients was 1.18, 1.41, and 1.14, respectively. Patients
with squamous cell carcinoma had significantly higher ex-
pression of Dicer and miR-126 than patients with adeno-
carcinoma (Additional file 1: Table S2). Using ≤ 2.0 as a
cut-off of expression (Additional file 2: Figure S1), about
70–80% of the patients had low expression and 20–30% ofthe patients had high expression of Dicer, Drosha, and
miR-126 (data not shown).
Performance status (ECOG), disease-specific survival
(DSS), and overall survival (OS) in NSCLC patient
groups—Univariate analyses
WHO performance status (ECOG, P = 0.013), histology
(P = 0.028), tumor differentiation (P < 0.001), surgical
procedure (P < 0.004), pathological stage (P < 0.001),
tumor status (P < 0.001), nodal status (P < 0.001), and
vascular infiltration (P < 0.001) were all significant indi-
cators for DSS in univariate analyses (Additional file 1:
Table S1 and [19]).
Patients with squamous cell carcinoma had signifi-
cantly longer DSS than lung cancer patients with other
histology (P = 0.035, Figure 1A). However, there were no
significant differences regarding overall survival between
patients with squamous cell carcinoma compared to pa-
tients with other histology (P = 0.447, Figure 1B). Pa-
tients with normal performance status (ECOG = 0) had
significantly longer DSS and overall survival than pa-
tients with reduced performance status (ECOG = 1–2),
P = 0.005 (Figure 1C) and P = 0.004 (Figure 1D).
Figure 2 Disease-specific survival curves for high and low expression of Dicer in NSCLC patients (n = 321) (A), in patients with
squamous cell carcinoma (n = 186) (B), in patients with other histology (n = 135) (C), in patients with normal performance status
(ECOG = 0, n = 191) (D), in patients with reduced performance status (ECOG = 1–2, n =140) (E), and in patients with squamous cell
carcinoma with normal performance status (ECOG = 0, n = 105) (F).
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Dicer was expressed in the cytoplasm of most neoplastic
tumor cells, and slight staining was observed in the nu-
cleus of some cells as well (Additional file 2: Figure S2).
Thirty-five patients (10.4%) scored negative on all four
cores. Drosha was primarily expressed in the nucleus,
but some staining was observed in the cytoplasm(Additional file 2: Figure S3). We found 14 patients
(4.2%) that scored negative on all four sample cores. In-
flammatory cells, pneumocytes, and fibroblasts showed
greater variability in expressing both Dicer and Drosha
when compared to tumor cells. A significant, but low
correlation between Dicer expression in cytoplasm and
Drosha expression in the nucleus of neoplastic tumor
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2: Figure S4).
The expression of Dicer (P = 0.008) and miR-126 (P =
0.020) was different in the tumor subgroups (see Additional
file 1: Table S2). Expression of Dicer was not correlated with
DSS when all patients were analyzed in one group (P =
0.167, Figure 2A). The expression of Dicer was of notFigure 3 Disease-specific survival curves for high and low expression
squamous cell carcinoma (n = 186) (B), in patients with other histolog
(ECOG = 0, n = 187) (D), in patients with reduced performance status (
carcinoma with normal performance status (ECOG = 0, n = 116) (F).correlated with DSS in patients with squamous cell carcin-
oma (P = 0.147, Figure 2B) or other histologies (P = 0,844,
Figure 2C). However, in patients with normal performance
status (ECOG= 0), high expression of Dicer was significantly
correlated with longer DSS (P = 0.024,) (Figure 2D), but no
differences in patients with reduced performance status
(ECOG= 1–2) were observed (P = 0.518, Figure 2E). Inof Drosha in NSCLC patients (n = 316) (A), in patients with
y (n = 130) (C), in patients with normal performance status
ECOG = 1–2, n =129) (E), and in patients with squamous cell
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performance status (ECOG= 0), high expression of Dicer
was significantly correlated with long DSS (P = 0.013,
Figure 2F). Expression of Drosha was not correlated with
DSS for any subgroups of histology and performance status
(Figure 3A– F).
When combining expression of Drosha and miR-126,
the subgroup of patients with both high Drosha and high
miR-126 expression had significantly shorter DSS
(P < 0.001) (Figure 4A) and overall survival (P = 0.001,
Figure 4B).
Multivariate cox proportional hazard analysis
Tumor status (T-stage, P = 0.002), nodal status (N-stage,
P < 0.001), performance status (0.003), vascular infiltra-
tion (P = 0.016), interaction of Dicer with histology
(Dicer*Histology, P = 0.049), and Drosha/miR-126 co-
expression (P = 0.033) were independently significantly
correlated with DSS (Table 1). In the subgroup of pa-
tients with both squamous cell carcinoma and normal
performance status (ECOG = 0, n = 107), tumor status
(P = 0.021), nodal status (P = 0.001), vascular infiltration
(P = 0.011), and expression of Dicer (P = 0.031), but not
tumor differentiation (P = 0.587), were independently
correlated with DSS (Table 2).
When Dicer and Drosha are analyzed on a continuous
scale (0–3) instead of two groups of expression (high
and low), none of them correlated with DSS in the total
patient material (Additional file 1: Table S3). To identify
other relevant factors regarding expression of Dicer, the
expression was tested by histology, performance status,
tumor differentiation, tumor status, nodal status, and
vascular infiltration. High expression was found in SCC
(P = 0.012) and in tumors with vascular infiltration (P =
0.035, Additional file 1: Table S4). The Dicer interaction
with histology was highly significant (P = 0.005, AdditionalFigure 4 Disease-specific survival (A) and overall survival (B) curves fo
material (n = 301).file 1: Table S5). This was not the case for Dicer inter-
action with ECOG (Additional file 1: Table S6) and Dicer
interaction with vascular infiltration (Additional file 1:
Table S7). The proportionality of hazards was tested
graphically and the results are depicted in Additional
file 2: Figure S5.
Co-expression of Drosha and miR-126
For co-expression analyses, we used miR-126 data ob-
tained by ISH of TMAs from a previously published
study [19] demonstrating that high miR-126 expression
is an independent negative prognostic factor in the total
patient cohort. As illustrated in Figure 4, a univariate
analysis found that the co-expression of Drosha and
miR-126 had a significant impact on DSS, with 5-year
survival rates of 58% (patients with low Drosha and low
miR-126 expression), 61% (low Drosha and high miR-
126 expression), 74% (high Drosha and low miR-126
expression), and 17% (high Drosha and high miR-126
expression) (p < 0.001). In a multivariate analysis, these
co-expressions were independent prognostic indicators
for DSS (p = 0.016). For patients with high Drosha/high
miR-126, the HR was 2.1 (1.1–4.0 at 95% CI, p < 0.001)
compared to patients with high Drosha/low miR-126
(Table 1).
Discussion
In this large-scale study comprising primary tumors
from 335 patients, we investigated the prognostic impact
of the miRNA regulators Dicer and Drosha in NSCLC.
The observed expression of the nuclear enzyme Drosha
and the cytoplasmic enzyme Dicer correlated positively
with each other, suggesting their mutual dependence in
the miRNA-regulatory pathway in NSCLC. Reduced
Dicer and Drosha expression has been reported in vari-
ous cancers, and based on previous publications onr co-expression of Drosha and miR-126 in the total patient
Table 1 Cox regression analysis summarizing significant
independent prognostic factors
Factor HR 95% CI P
Tumor status 0.002*
1 1.00
2 1.54 0.91 – 2.59 0.108
3 2.73 1.53 – 4.90 0.001
Nodal status <0.001*
0 1.00
1 1.98 1.27 – 3.08 0.003
2 3.13 1.80 – 5.46 <0.001
Histology
SCC 1.00
Other NSCLC 0.99 0.500 – 1.98 0.986
Differentiation 0.094*
Poor 1.00
Moderate 0.70 0.46 – 1.05 0.083
Well 0.56 0.29 – 1.10 0.095
Performance status
ECOG = 0 1.00
ECOG = 1-2 1.80 1.23 – 2.64 0.003
Vascular infiltration
No 1.00
Yes 1.82 1.12 – 2.98 0.016
Dicer** 0.87 0.65 – 1.16 0.333
Dicer*Histology*** 1.27 1.00 – 1.61 0.049
Drosha / miR-126 0.033*
Low / Low 1.00
Low / High 1.13 0.62 – 2.05 0.696
High / Low 0.63 0.37 – 1.07 0.089
High / High 1.96 1.04 – 3.69 0.037
*Overall significance as a prognostic factor.
**B = −0.141.
***B = 0.240.
Dicer*Histology = the interaction between Dicer and Histology.
HR: Hazard ration; CI: confidence interval.
Table 2 Cox regression analysis summarizing significant
independent prognostic factors in patients with
squamous cell carcinoma and normal performance status
(ECOG = 0), n = 107
Factor HR 95% CI P
Tumor status 0.021*
1 1.00
2 2.52 0.82 – 7.79 0.108
3 5.11 1.54 – 16.89 0.008
Nodal status 0.001*
0 1.00
1 2.11 1.21 – 2.89 0.045
2 20.06 3.70 – >99 0.001
Differentiation 0.587*
Poor 1.00
Moderate 0.64 0.26 – 1.56 0.328
Well 0.72 0.23 – 2.26 0.578
Vascular infiltration
No 1.00
Yes 3.10 1.29 – 7.42 0.011
Dicer
Low 1.00
High 0.30 0.10 – 0.90 0.031
*Overall significance as a prognostic factor.
HR: Hazard ratio; CI: confidence interval.
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Dicer and Drosha would have a positive prognostic im-
pact on DSS, where reduced Dicer and Drosha expres-
sion would entail a poorer prognosis compared to higher
expressions. Our results found no significant association
between the miRNA regulators and DSS (Figure 2A).
Dicer is usually reported as a more powerful prognosti-
cator for survival than Drosha [27,28]. Stratified by
ECOG, Dicer expression turned out to be significant for
patients with normal performance status (ECOG = 0)
only (Figure 2D). In general, patients with reduced per-
formance status (ECOG = 1–4) have a more advanced
disease and poor prognosis, independent of the tumor’sbiological properties [33]. This might explain why Dicer
expression had no impact on survival in this group of
patients, and might also explain the differences of Dicer
impact compared with other NSCLC studies, where
ECOG performance is rarely mentioned. Our results
clearly show that low Dicer expression is a significant
negative prognostic marker in patients with normal per-
formance status ECOG = 0 (Figure 2D). This patient
group might therefore have an advantage in receiving
adjunctive treatment. In addition, for patients with nor-
mal ECOG performance status, the low expression of
Dicer was positively correlated with better survival rates
in the patient group with squamous cell carcinoma (see
Figure 2F), whereas Dicer expression had no prognostic
impact on other histological subgroups (data not
shown).
Dicer, Drosha, and miRNAs are involved in cell growth
and differentiation, implying an impact on tumorigenesis
[39]. Various studies focusing on Dicer and/or Drosha
have confirmed this theory and revealed that these two
regulators of the miRNA processing pathway play either
a positive or a negative role in tumor transformation.
There is evidence that reduced Dicer expression is asso-
ciated with poor prognosis in NSCLC [28]. However,
in vitro experiments showed that silencing of Dicer and
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found that increased expression of Dicer correlates with
better prognosis. Neuroblastoma and leukemia are two
other examples where low levels of Dicer and Drosha are
significant predictive factors for poor outcomes [27,40]. In
other types of cancer, the importance of Dicer and Drosha
might be the opposite. A recent study by Faber et al. using
TMA technology and a scoring system like the one de-
scribed here, found evidence that Dicer is a negative prog-
nosticator for DSS in colorectal cancer [41]. Clearly, the
functions of Dicer and Drosha are not fully understood in
cancer development, and their functions appear to vary
between different cancer types [42-44].
In most cancers, the majority of all miRNAs are down-
regulated, suggesting that most miRNAs have tumor
suppressive effects [44]. Regulation of miRNA biogenesis
is a complex process involving a myriad of different en-
zymes and proteins, where Dicer and Drosha are two
key regulators necessary for the processing of most func-
tional, mature miRNAs. We previously described the
prognostic impact of miR-126 in NSCLC [19], where the
co-expression of miR-126 and VEGF-A was a strong
predictor for poor survival. We know that VEGF-A is a
potent angiogenesis promoter, and miR-126 has been
linked to angiogenesis in several other studies [11,45,46].
Interestingly, we found that the co-expression of Drosha
and miR-126 also predicts poor survival, which is even
more significant than the co-expression of miR-126 and
VEGF-A reported previously [19]. Although not signifi-
cant (p = 0.06), the combination of high Drosha and low
miR-126 was the most favorable in relation to DSS (see
Table 1), suggesting that Drosha in itself is not a good
prognostic marker for overall survival in NSCLC, which
is consistent with our univariate analyses (see Figure 3A).
We tested the co-expressions of both Dicer and Drosha,
in combination with the miRNAs miR-126 and miR-155
[47] in all 335 patients, and miR122a and let-7a in 40
randomly selected patients (data not shown). These tests
demonstrated that the only combination with impact
on DSS was the Drosha and miR-126 combination (see
Figure 4). The significance of Drosha, as well as Dicer, in
driving angiogenesis in vitro has been reported previ-
ously [24]. However, in vivo experiments showed that
only Dicer reduces angiogenesis [48]. Our results imply
that Drosha in itself is not a good prognostic marker in
NSCLC, and that the effect of Drosha might be
influenced by different miRNAs involved in tumor
angiogenesis.
In addition, Dicer-independent, and probably Drosha-
independent maturing of miRNAs is possible, suggesting al-
ternative pathways and different roles for Dicer and Drosha
in various cancers [49,50]. As an example, miR-451 is proc-
essed by Ago, without the need for Dicer [51]. Several stud-
ies have also shown that knockdown of Dicer and Droshaonly reduces a subset of miRNAs, implying alternative path-
ways for miRNA synthesis [49-51]. Further studies are
clearly needed to investigate these possibilities.
Conclusion
The immunohistochemical approach reveals the varying
presence of Dicer and Drosha in NSCLC tumors, and
these two enzymes may be important in NSCLC develop-
ment. Our research points to Dicer as an important factor
in regard to DSS in patients with normal ECOG, and im-
plies that Drosha in combination with miR-126 and pos-
sibly other angiogenesis-related miRNAs, is a strong and
important prognosticator for DSS in NSCLC. The Dicer
and Drosha expression status in various histologic sub-
types of lung cancer and at different stages of lung cancer
development might explain abnormalities in miR profiles
of NSCLC. Additional studies are needed, since optimized
treatment of NSCLC requires better identification of high-
risk patients who will benefit from adjuvant therapy.
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